ImmunoGen, Inc. Announces Clinical Data For T-DM1 Used In Combination With Pertuzumab

[News]

ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology, announced the presentation of the first clinical data for trastuzumab-DM1 (T-DM1) used in combination with pertuzumab for first-line treatment of HER2+ metastatic breast cancer (mBC)...

More... (http://mnt.to/f/3PbY)

[Unregistered]

Is Pertuzumab approved by FDA or it could be use in clinical trials only?

[chrisy]

Not approved by fda yet